Stock A8D AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

Financials AB Science Deutsche Boerse AG

Equities

A8D

FR0010557264

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 03:48:39 01/07/2024 pm IST 		5-day change 1st Jan Change
1.096 EUR -0.36% Intraday chart for AB Science -7.85% -70.25%
28/06 AB Science: negative CHMP opinion for masitinib in ALS CF
03/06 AB Science: share price falls on resumption of trading CF

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 237 895.3 332.2 180.9 65.99 - -
Enterprise Value (EV) 1 237 895.3 332.2 180.9 65.99 65.99 65.99
P/E ratio - - -24.4 x -17.8 x -3.1 x -3.02 x -2.86 x
Yield - - - - - - -
Capitalization / Revenue 151 x 566 x - 187 x 66.7 x 60 x 55.5 x
EV / Revenue 151 x 566 x - 187 x 66.7 x 60 x 55.5 x
EV / EBITDA - - - - -3.69 x -3.51 x -3.4 x
EV / FCF - - - - -3.67 x -3.47 x -3.22 x
FCF Yield - - - - -27.3% -28.8% -31%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 44,060 45,540 46,861 50,891 59,133 - -
Reference price 2 5.380 19.66 7.090 3.555 1.116 1.116 1.116
Announcement Date 30/04/20 30/04/21 01/03/23 15/05/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net sales 1 1.571 1.583 - 0.97 0.99 1.1 1.19
EBITDA 1 - - - - -17.89 -18.78 -19.41
EBIT 1 -17.47 - - -13.43 -15.91 -15.8 -15.7
Operating Margin -1,112.29% - - -1,384.43% -1,607.07% -1,436.36% -1,319.33%
Earnings before Tax (EBT) - - - - - - -
Net income 1 - - -13.62 -10.05 -18.77 -18 -16.96
Net margin - - - -1,035.88% -1,895.96% -1,636.36% -1,425.21%
EPS 2 - - -0.2900 -0.2000 -0.3600 -0.3700 -0.3900
Free Cash Flow 1 - - - - -17.99 -19 -20.49
FCF margin - - - - -1,817.17% -1,727.27% -1,721.85%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 30/04/20 30/04/21 01/03/23 15/05/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - - -18 -19 -20.5
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - - - - 0.06 0.5 1.27
Capex / Sales - - - - 6.06% 45.45% 106.72%
Announcement Date 30/04/20 30/04/21 01/03/23 15/05/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.116 EUR
Average target price
6.895 EUR
Spread / Average Target
+517.83%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+6.38% 72.09B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+16.96% 9.05B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-22.81% 4.4B
YUHAN CORPORATION Stock Yuhan Corporation
+17.59% 4.39B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+25.93% 3.94B
INDIVIOR PLC Stock Indivior PLC
+3.21% 2.1B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+9.09% 1.97B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-36.86% 1.87B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AB Stock
  4. A8D Stock
  5. Financials AB Science